SpyGlass Pharma initiated with a Buy at Jefferies

Jefferies analyst Dennis Ding initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $62 price target SpyGlass is developing a “compelling” long-acting drug release platform for the eye, says the analyst, who sees 75% odds of success for the Phase 3 study due to report in late 2027 for glaucoma. This would enable a “compelling launch” in 2029, adds the analyst, who estimates $2B-plus in peak sales.